Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
29 mars 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Reports 2022 Financial Results and Operational Progress
23 mars 2023 06h30 HE
|
Affimed N.V.
AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24:...
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
16 mars 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
14 mars 2023 16h30 HE
|
Affimed N.V.
An oral presentation on the safety and efficacy from the AFM13 phase 2 monotherapy clinical study (“REDIRECT”) in patients with CD30-positive relapsed or refractory (R/R) peripheral T-cell lymphoma...
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
09 mars 2023 05h00 HE
|
Affimed N.V.
PLZEN, Czech Republic, March 09, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced...
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
22 févr. 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
21 févr. 2023 05h00 HE
|
Affimed N.V.
PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced...
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
08 févr. 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
09 janv. 2023 06h30 HE
|
Affimed N.V.
AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of...
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
22 déc. 2022 06h30 HE
|
Affimed N.V.
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of...